Biopharmaceutical company Ascendis Pharma (NASDAQ:ASND) and Visen Pharmaceuticals’ long-acting growth hormone lonapegsomatropin has demonstrated superior efficacy to daily hGH in a pivotal Phase 3 study in children with growth hormone deficiency.
The drug has been licensed by ASND to Visen and is being developed in Greater China. The once-a-week injection has shown an annualized height velocity of 10.66 cm/year versus 9.75 cm/year for daily hGH over a period of 52 weeks.
Further, the injection was well tolerated in trial subjects. Lonapegsomatropin was approved by the U.S. Food and Drug Administration earlier this year.
Ascendis shares have gained 35.5% over the past six months.
Read full Disclosure
